Roubaix Capital LLC lessened its position in Shoulder Innovations, Inc. (NYSE:SI – Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 229,944 shares of the company’s stock after selling 25,344 shares during the period. Roubaix Capital LLC owned about 1.10% of Shoulder Innovations worth $4,346,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in SI. Russell Investments Group Ltd. grew its holdings in shares of Shoulder Innovations by 2,151.8% during the third quarter. Russell Investments Group Ltd. now owns 73,025 shares of the company’s stock valued at $1,380,000 after buying an additional 69,782 shares during the last quarter. Royal Bank of Canada raised its holdings in Shoulder Innovations by 7,046.3% in the 1st quarter. Royal Bank of Canada now owns 53,883 shares of the company’s stock worth $783,000 after acquiring an additional 53,129 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Shoulder Innovations in the 2nd quarter worth approximately $896,000. CenterBook Partners LP purchased a new position in Shoulder Innovations in the 3rd quarter worth approximately $784,000. Finally, KCM Capital Inc bought a new position in Shoulder Innovations in the 1st quarter valued at approximately $509,000.
Wall Street Analysts Forecast Growth
Several brokerages have commented on SI. UBS Group increased their target price on Shoulder Innovations from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d)” rating on shares of Shoulder Innovations in a report on Friday, October 30th. BTIG Research boosted their price target on Shoulder Innovations from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target (up from $19.00) on shares of Shoulder Innovations in a report on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.75.
Read Our Latest Stock Report on SI
Insider Buying and Selling
In other Shoulder Innovations news, CEO Robert Ball sold 10,175 shares of Shoulder Innovations stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.45, for a total value of $187,728.75. Following the completion of the sale, the chief executive officer owned 380,824 shares of the company’s stock, valued at approximately $7,026,202.80. The trade was a 2.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Healthcare Holding B.V. Gilde sold 20,516 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $22.61, for a total transaction of $463,866.76. Following the sale, the insider owned 2,187,791 shares of the company’s stock, valued at approximately $49,465,954.51. This represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 36,468 shares of company stock worth $782,169. 29.00% of the stock is owned by insiders.
Shoulder Innovations Stock Performance
Shares of NYSE SI opened at $20.52 on Wednesday. The firm’s 50-day moving average price is $19.08 and its 200-day moving average price is $17.40. The company has a quick ratio of 8.69, a current ratio of 10.68 and a debt-to-equity ratio of 0.13. Shoulder Innovations, Inc. has a 52-week low of $12.00 and a 52-week high of $24.59.
Shoulder Innovations (NYSE:SI – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.15. Shoulder Innovations had a negative net margin of 51.72% and a negative return on equity of 25.37%. The firm had revenue of $16.19 million during the quarter. As a group, equities analysts predict that Shoulder Innovations, Inc. will post -1.70 earnings per share for the current year.
Shoulder Innovations Company Profile
Shoulder Innovations, Inc. is a medical technology company focused on developing and commercializing products for shoulder replacement surgery. Its offerings are designed for orthopedic surgeons treating patients with shoulder conditions that may require joint replacement. The company’s product portfolio includes shoulder implant systems such as its InSet glenoid and Catalyst reverse shoulder technologies, along with related surgical instruments. These products support different approaches to shoulder arthroplasty, including procedures that replace or reconstruct parts of the shoulder joint.
Featured Stories
- Five stocks we like better than Shoulder Innovations
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding SI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shoulder Innovations, Inc. (NYSE:SI – Free Report).
Receive News & Ratings for Shoulder Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shoulder Innovations and related companies with MarketBeat.com's FREE daily email newsletter.
